RYTM vs ACMR vs HALO vs ICHR vs ALNY

For growth investors, Alnylam Pharmaceuticals, Inc.

(ALNY) is the stronger pick with 65. 2% revenue growth year-over-year, versus 11. 6% for Ichor Holdings, Ltd. (ICHR). Halozyme Therapeutics, Inc. (HALO) offers the better valuation at 25. 5x trailing P/E (8. 1x forward), making it the more compelling value choice. Analysts rate Rhythm Pharmaceuticals, Inc. (RYTM) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Halozyme Therapeutics, Inc.

(HALO) is the cheapest at 25. 5x versus Alnylam Pharmaceuticals, Inc. at 127. 0x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Halozyme Therapeutics, Inc. wins at 0. 35x versus ACM Research, Inc. 's 0. 84x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Rhythm Pharmaceuticals, Inc.

(RYTM) delivered a total return of +335. 0%, compared to +28. 9% for Ichor Holdings, Ltd. (ICHR). Over 10 years, the gap is even starker: ACMR returned +30. 7% versus RYTM's +220. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.

(HALO) is the lower-risk stock at 0. 56β versus Ichor Holdings, Ltd. 's 3. 93β — meaning ICHR is approximately 604% more volatile than HALO relative to the S&P 500. On balance sheet safety, ACM Research, Inc. (ACMR) carries a lower debt/equity ratio of 16% versus 177% for Rhythm Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Alnylam Pharmaceuticals, Inc.

(ALNY) is pulling ahead at 65. 2% versus 11. 6% for Ichor Holdings, Ltd. (ICHR). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to -140. 6% for Ichor Holdings, Ltd.. Over a 3-year CAGR, RYTM leads at 100. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Halozyme Therapeutics, Inc.

(HALO) is the more profitable company, earning 22. 7% net margin versus -103. 6% for Rhythm Pharmaceuticals, Inc. — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -101. 2% for RYTM. At the gross margin level — before operating expenses — RYTM leads at 89. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Halozyme Therapeutics, Inc. (HALO) is the more undervalued stock at a PEG of 0. 35x versus ACM Research, Inc. 's 0. 84x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Halozyme Therapeutics, Inc. (HALO) trades at 8. 1x forward P/E versus 62. 2x for Ichor Holdings, Ltd. — 54. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALNY: 50. 6% to $445. 67.

In this comparison, ACMR (0.

2% yield) pays a dividend. RYTM, HALO, ICHR, ALNY do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +570. 7% 10Y return). ACM Research, Inc. (ACMR) carries a higher beta of 3. 24 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HALO: +570. 7%, ACMR: +30. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RYTM (Healthcare) and ACMR (Technology) and HALO (Healthcare) and ICHR (Technology) and ALNY (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: RYTM is a small-cap high-growth stock; ACMR is a small-cap high-growth stock; HALO is a small-cap high-growth stock; ICHR is a small-cap quality compounder stock; ALNY is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.